1. |
Study. J Clin Oncol, 2006, 24(9): 1435-1442.
|
2. |
Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. Form the International Mesothelioma Interest Group. Lung cancer, 1996, 14(1): 1-12.
|
3. |
Ellis P, Davies AM, Evans WK, et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol, 2006, 1(6): 591-601.
|
4. |
Green J, Dundar Y, Dodd S, et al. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. Cochrane Database of Systematic Reviews. 2007 Issue 1: CD005574.
|
5. |
Fizazi K, Caliandro R, Soulié P, et al. Combination raltitrexed (Tomudex)- oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer, 2000, 36(12): 1514-1521.
|
6. |
van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol, 2005, 23(28): 6881-6889.
|
7. |
Bottomley A, Gaafar R, Manegold C, et al. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup.
|
8. |
Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 2003, 21(14): 2636-2644.
|
9. |
O’Brien ME, Watkins D, Ryan C, et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol, 2006, 17(2): 270-275.
|
10. |
Muers MF, Rudd RM, O’Brien ME, et al. BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax, 2004, 59(2): 144-148.
|
11. |
Dundar Y, Bagust A, Dickson R, et al. Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation. Health Technol Assess, 2007, 11(1): 1-90.
|
12. |
Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organization classification of tumours. Pathology &genetics tumours of the lung, pleural, thymus and heart. Lyon: IARC Press, 2004.
|